American Shared Hospital Services (AMS) 10-Q 12 May 16 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 01, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Entity Registrant Name	AMERICAN SHARED HOSPITAL SERVICES
Entity Central Index Key	744,825
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	AMS
Entity Common Stock, Shares Outstanding		5,364,000

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 2,140,000	$ 2,209,000
Restricted cash	50,000	50,000
Accounts receivable, net of allowance for doubtful accounts of $100,000 at March 31, 2016 and $100,000 at December 31, 2015	3,557,000	3,038,000
Other receivables	88,000	107,000
Prepaid expenses and other current assets	531,000	570,000
Total current assets	6,366,000	5,974,000
Property and equipment:
Medical equipment and facilities	83,367,000	83,267,000
Office equipment	722,000	721,000
Deposits and construction in progress	17,899,000	10,796,000
Property and equipment	101,988,000	94,784,000
Accumulated depreciation and amortization	(49,228,000)	(47,661,000)
Net property and equipment	52,760,000	47,123,000
Investment in equity securities	579,000	579,000
Other assets	382,000	366,000
Total assets	60,087,000	54,042,000
Current liabilities:
Accounts payable	531,000	375,000
Employee compensation and benefits	198,000	156,000
Other accrued liabilities	1,052,000	1,162,000
Current portion of long-term debt	2,637,000	2,641,000
Current portion of obligations under capital leases	4,767,000	4,331,000
Total current liabilities	9,185,000	8,665,000
Long-term debt, less current portion	5,567,000	6,884,000
Long-term capital leases, less current portion	15,697,000	9,190,000
Deferred revenue, less current portion	689,000	719,000
Deferred income taxes	3,468,000	3,404,000
Shareholders' equity:
Common stock (10,000,000 authorized; 5,364,000 shares issued and outstanding at March 31, 2016 and December 31, 2015)	10,376,000	10,376,000
Additional paid-in capital	5,793,000	5,734,000
Retained earnings	4,071,000	4,020,000
Total equity-American Shared Hospital Services	20,240,000	20,130,000
Non-controlling interest in subsidiary	5,241,000	5,050,000
Total shareholders' equity	25,481,000	25,180,000
Total liabilities and shareholders' equity	$ 60,087,000	$ 54,042,000

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Allowance for doubtful accounts (in dollars)	$ 100,000	$ 100,000
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	5,364,000	5,364,000
Common stock, shares outstanding	5,364,000	5,364,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenue:
Medical services revenue	$ 4,238,000	$ 4,117,000
Costs of revenue:
Maintenance and supplies	244,000	333,000
Depreciation and amortization	1,562,000	1,505,000
Other direct operating costs	699,000	682,000
Costs of revenue	2,505,000	2,520,000
Gross Margin	1,733,000	1,597,000
Selling and administrative expense	949,000	821,000
Interest expense	285,000	320,000
Operating income	499,000	456,000
(Loss) on early extinguishment of debt	(108,000)	0
Interest and other income	5,000	6,000
Income before income taxes	396,000	462,000
Income tax expense	64,000	130,000
Net income	332,000	332,000
Less: Net income attributable to non-controlling interest	(281,000)	(204,000)
Net income attributable to American Shared Hospital Services	$ 51,000	$ 128,000
Net income per share:
Earnings per common share - basic	$ 0.01	$ 0.02
Earnings per common share - diluted	$ 0.01	$ 0.02

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Sub-Total ASHS [Member]	Non-controlling Interest [Member]
Balances at Dec. 31, 2014	$ 26,154,000	$ 10,376,000	$ 5,508,000	$ 5,542,000	$ 21,426,000	$ 4,728,000
Balances (in shares) at Dec. 31, 2014		5,361,000
Stock based compensation expense	226,000	$ 0	226,000	0	226,000	0
Stock based compensation expense (in shares)		3,000
Non-controlling interest investment in subsidiaries	46,000	$ 0	0	0	0	46,000
Cash distributions to non-controlling interests	(670,000)	0	0	0	0	(670,000)
Net (loss) income	(576,000)	0	0	(1,522,000)	(1,522,000)	946,000
Balances at Dec. 31, 2015	25,180,000	$ 10,376,000	5,734,000	4,020,000	20,130,000	5,050,000
Balances (in shares) at Dec. 31, 2015		5,364,000
Stock based compensation expense	59,000	$ 0	59,000	0	59,000	0
Stock based compensation expense (in shares)		0
Non-controlling interest investment in subsidiaries	7,000	$ 0	0	0	0	7,000
Cash distributions to non-controlling interests	(97,000)	0	0	0	0	(97,000)
Net (loss) income	332,000	0	0	51,000	51,000	281,000
Balances at Mar. 31, 2016	$ 25,481,000	$ 10,376,000	$ 5,793,000	$ 4,071,000	$ 20,240,000	$ 5,241,000
Balances (in shares) at Mar. 31, 2016		5,364,000

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating activities:
Net income	$ 332,000	$ 332,000
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	1,574,000	1,517,000
(Gain) on sale of assets	(1,000)	0
Loss on early extinguishment of debt	108,000	0
Deferred income tax	64,000	0
Stock-based compensation expense	59,000	36,000
Other non-cash items	4,000	12,000
Changes in operating assets and liabilities:
Receivables	(500,000)	(735,000)
Prepaid expenses and other assets	22,000	9,000
Customer deposits/deferred revenue	(78,000)	17,000
Accounts payable and accrued liabilities	136,000	141,000
Net cash from operating activities	1,720,000	1,329,000
Investing activities:
Payment for purchase of property and equipment	(333,000)	(188,000)
Net cash used in investing activities	(333,000)	(188,000)
Financing activities:
Principal payments on long-term debt	(1,439,000)	(401,000)
Principal payments on capital leases	(1,064,000)	(1,004,000)
Proceeds from certificate of deposit	0	9,000,000
Payments on line of credit	0	(8,780,000)
Capital contributions from non-controlling interests	7,000	0
Distributions to non-controlling interests	(97,000)	(88,000)
Proceeds from capital lease financing for reimbursement of payments for acquisition of equipment	1,137,000	0
Net cash used in financing activities	(1,456,000)	(1,273,000)
Net change in cash and cash equivalents	(69,000)	(132,000)
Cash and cash equivalents at beginning of period	2,209,000	1,059,000
Cash and cash equivalents at end of period	2,140,000	927,000
Supplemental cash flow disclosure:
Interest	515,000	438,000
Income taxes (refunds)	96,000	(5,000)
Schedule of non-cash investing and financing activities
Acquisition of equipment with capital lease financing	$ 6,870,000	$ 1,160,000

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Basis of Presentation In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly American Shared Hospital Services’ consolidated financial position as of March 31, 2016 and the results of its operations for the three month periods ended March 31, 2016 and 2015, which results are not necessarily indicative of results on an annualized basis. Consolidated balance sheet amounts as of December 31, 2015 have been derived from audited consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2015 included in the Company’s 10-K filed with the Securities and Exchange Commission. These condensed consolidated financial statements include the accounts of American Shared Hospital Services (the “Company”) and its subsidiaries as follows: The Company wholly-owns the subsidiaries OR21, Inc. (“OR21 LLC”), MedLeader.com, Inc. (“MedLeader”), PBRT Orlando, LLC (“Orlando”) and American Shared Radiosurgery Services (“ASRS”). The Company is also the majority owner of Long Beach Equipment, LLC (“LBE”). ASRS is the majority-owner of GK Financing, LLC (“GKF”) which wholly-owns the subsidiaries GK Financing U.K., Limited (“GKUK”), and Instituto de Gamma Knife del Pacifico S.A.C. (“GKPeru”). GKF is also the majority-owner of the subsidiaries Albuquerque GK Equipment, LLC (“AGKE”) and Jacksonville GK Equipment, LLC (“JGKE”). The Company through its majority-owned subsidiary, GKF, provided Gamma Knife units to seventeen medical centers as of March 31, 2016 in the states of Arkansas, California, Oregon, Connecticut, Florida, Illinois, Massachusetts, Mississippi, Nevada, New Jersey, New Mexico, New York, Tennessee, Oklahoma, Ohio, Texas, and Washington. The Company also directly provides radiation therapy and related equipment, including Intensity Modulated Radiation Therapy (“IMRT”), Image Guided Radiation Therapy (“IGRT”) and a CT Simulator to the radiation therapy department at an existing Gamma Knife site in the United States. The Company formed the subsidiaries GKUK and GKPeru, for the purposes of expanding its business internationally into the United Kingdom and Peru; LBE and Orlando to provide proton beam therapy services in Long Beach, California and Orlando, Florida; and AGKE and JGKE to provide Gamma Knife services in Albuquerque, New Mexico and Jacksonville, Florida. AGKE began operation in the second quarter 2011 and JGKE began operation in the fourth quarter 2011. Orlando treated its first patient in April 2016. GKPeru is expected to begin operation in mid-2016. GKUK is inactive and LBE is not expected to generate revenue within the next two years. The Company continues to develop its design and business model for “The Operating Room for the 21st Century” SM (“OR21” SM 50 50 MedLeader was formed to provide continuing medical education online and through videos for doctors, nurses and other healthcare workers. This subsidiary is not operational at this time. Based on the guidance provided in accordance with Accounting Standards Codification (“ASC”) 280 Segment Reporting On January 14, 2016, the Company entered into a definitive lease agreement for financing of its MEVION S250 at UF Health Cancer Center at Orlando Health. The proceeds of $ 7,900,000 8,400,000 1,000,000 6,700,000 1,137,000 Based on the guidance provided in accordance with ASC 405 Extinguishment of Liabilities Debt Modifications and Extinguishments 108,000 145,000 80,000 28,000 In May 2014, the Financial Accounting Standards Board “(FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers In August 2014, FASB issued ASU No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern In January 2015, the FASB issued ASU No. 2015-01, Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items , Presentation of Financial Statements In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis In April 2015, the FASB issued ASU No. 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs The Company adopted ASU 2015-03 on January 1, 2016, on a retrospective basis. Debt issuance costs that were previously recorded as other assets on the Company’s condensed consolidated Balance Sheets were reclassified as an offset to the respective debt instrument for which they were derived. As of March 31, 2016 and December 31, 2015, $ 67,000 72,000 In January 2016, the FASB issued ASU No. 2016-01 Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02 Leases In March 2016, the FASB issued ASU No. 2016-09 Compensation – Stock Compensation (Topic 718)

Per Share Amounts

Per Share Amounts	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Per Share Amounts Per share information has been computed based on the weighted average number of common shares and dilutive common share equivalents outstanding. The computation for the three month periods ended March 31, 2016 and 2015 excluded approximately 617,000 Three Months ended March 31, 2016 2015 Net income attributable to American Shared Hospital Services $ 51,000 $ 128,000 Weighted average common shares for basic earnings per share 5,541,000 5,477,000 Diluted effect of stock options and restricted stock - 49,000 Weighted average common shares for diluted earnings per share 5,541,000 5,526,000 Basic earnings per share $ 0.01 $ 0.02 Diluted earnings per share $ 0.01 $ 0.02

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Stock-based Compensation On June 2, 2010, the Company’s shareholders approved an amendment and restatement of the 2006 Stock Incentive Plan (the “2006 Plan”). Among other things, the amendment and restatement renamed the 2006 Plan to the Incentive Compensation Plan (the “Plan”) and increased the number of shares of the Company’s common stock reserved for issuance under the Plan by an additional 880,000 750,000 1,630,000 Stock-based compensation expense associated with the Company’s stock-based options to employees is calculated using the Black-Scholes valuation model. The Company’s stock-based awards have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimates. The estimated fair value of the Company’s option grants is estimated using assumptions for expected life, volatility, dividend yield, and risk-free interest rate which are specific to each award. The estimated fair value of the Company’s options is amortized over the period during which an employee is required to provide service in exchange for the award (requisite service period), usually the vesting period. Accordingly, stock-based compensation cost before income tax effect, for the Company’s options and restricted stock awards, in the amount of $ 59,000 36,000 440,000 Restricted Grant Date Intrinsic Outstanding at January 1, 2016 3,000 $ 2.58 $ - Granted 32,000 $ 1.89 $ - Vested (8,000) $ 1.89 $ - Forfeited - $ - $ - Outstanding at March 31, 2016 27,000 $ 1.97 $ 7000 Stock Grant Date Weighted- Outstanding at January 1, 2016 614,000 $ 2.86 5.10 Granted 3,000 $ 1.90 6.94 Exercised - $ - - Forfeited - $ - - Outstanding at March 31, 2016 617,000 $ 2.85 4.86 Exercisable at March 31, 2016 82,000 $ 2.74 2.69

Investment in Equity Securities

Investment in Equity Securities	3 Months Ended
	Mar. 31, 2016
Investments, All Other Investments [Abstract]
Cost-method Investments, Description [Text Block]	Investment in Equity Securities As of March 31, 2016 and December 31, 2015 the Company had a $ 579,000 0.46 The Company carries its investment in Mevion at cost and reviews it for impairment on a quarterly basis, or as events or circumstances might indicate that the carrying value of the investment may not be recoverable. During the period ended December 31, 2015, the Company determined that its investment was other than temporarily impaired. In determining the fair value of the Company’s common stock in Mevion, the Company engaged a third party expert to review and corroborate its assessment of the fair value of the investment. The third party utilized the market approach and an option waterfall model calibrated to Mevion’s last round of funding. Each equity class was examined and priced according to its liquidation preferences. The fair value of the Company’s investment in Mevion, as of December 31, 2015, was approximately $ 579,000 2,140,000 The Company reviewed this investment at March 31, 2016 in light of both current market conditions and the ongoing needs of Mevion to raise cash to continue its development of the first compact, single room proton beam radiation therapy (“PBRT”) system. Based on its analysis, the Company determined no additional impairment needs to be recognized as of March 31, 2016. The first MEVION S250, located at Barnes-Jewish Hospital in St. Louis, MO (“Barnes-Jewish Hospital”), treated its first patient on December 19, 2013. The second MEVION S250, located at the Ackerman Cancer Center in Jacksonville, Florida (“Ackerman Cancer Center”), treated its first patient in April 2015. The third MEVION S250, located at Robert Wood Johnson University Hospital in New Brunswick, New Jersey (“Robert Wood Johnson”), started in May 2015. The Company’s first MEVION S250 treated its first patient on April 6, 2016.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 5. Fair Value of Financial Instruments The Company’s disclosures of the fair value of financial instruments is based on a fair value hierarchy which prioritizes the inputs to the valuation techniques used to measure fair value into three levels. Level 1 inputs are unadjusted quoted market prices in active markets for identical assets and liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for assets or liabilities, and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability. Level 1 Level 2 Level 3 Total Carrying March 31, 2016 Assets: Cash, cash equivalents, restricted cash $ 2,190 $ - $ - $ 2,190 $ 2,190 Investment in equity securities - - 579 579 579 Total $ 2,190 $ - $ 579 $ 2,769 $ 2,769 Liabilities Debt obligations $ - $ - $ 8,321 $ 8,321 $ 8,204 Total $ - $ - $ 8,321 $ 8,321 $ 8,204 December 31, 2015 Assets: Cash, cash equivalents, restricted cash $ 2,259 $ - $ - $ 2,259 $ 2,259 Investment in equity securities - - 579 579 579 Total $ 2,259 $ - $ 579 $ 2,838 $ 2,838 Liabilities Debt obligations $ - $ - $ 9,744 $ 9,744 $ 9,525 Total $ - $ - $ 9,744 $ 9,744 $ 9,525

Repurchase of Common Stock

Repurchase of Common Stock	3 Months Ended
	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 6. Repurchase of Common Stock In 1999 and 2001, the Board of Directors approved resolutions authorizing the Company to repurchase up to a total of 1,000,000 shares of its own stock on the open market, which the Board reaffirmed in 2008. There were no shares repurchased in 2016 or 2015. There are approximately 72,000 shares remaining under this repurchase authorization.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 7. Income Taxes We generally calculate our effective income tax rate at the end of an interim period using an estimate of the annualized effective income tax rate expected to be applicable for the full fiscal year. However, when a reliable estimate of the annualized effective income tax rate cannot be made, we compute our provision for income taxes using the actual effective income tax rate for the results of operations reported within the year-to-date periods. Our effective income tax rate is highly influenced by relative income or losses reported and the amount of the nondeductible stock-based compensation associated with grants of our common stock options and historically from the results of foreign operations. A small change in estimated annual pretax income (loss) can produce a significant variance in the annualized effective income tax rate given the expected amount of these items. As a result, we have computed our provision for income taxes for the three month periods ended March 31, 2016 and 2015 by applying the actual effective tax rates to income reported within the condensed consolidated financial statements through those periods.

Per Share Amounts (Tables)

Per Share Amounts (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table sets forth the computation of basic and diluted earnings per share for the three month periods ended March 31, 2016 and 2015: Three Months ended March 31, 2016 2015 Net income attributable to American Shared Hospital Services $ 51,000 $ 128,000 Weighted average common shares for basic earnings per share 5,541,000 5,477,000 Diluted effect of stock options and restricted stock - 49,000 Weighted average common shares for diluted earnings per share 5,541,000 5,526,000 Basic earnings per share $ 0.01 $ 0.02 Diluted earnings per share $ 0.01 $ 0.02

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	The following table summarizes unvested restricted stock awards, consisting primarily of annual automatic grants and deferred compensation to non-employee directors, for the three month period ended March 31, 2016: Restricted Grant Date Intrinsic Outstanding at January 1, 2016 3,000 $ 2.58 $ - Granted 32,000 $ 1.89 $ - Vested (8,000) $ 1.89 $ - Forfeited - $ - $ - Outstanding at March 31, 2016 27,000 $ 1.97 $ 7000
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes stock option activity for the three month period ended March 31, 2016: Stock Grant Date Weighted- Outstanding at January 1, 2016 614,000 $ 2.86 5.10 Granted 3,000 $ 1.90 6.94 Exercised - $ - - Forfeited - $ - - Outstanding at March 31, 2016 617,000 $ 2.85 4.86 Exercisable at March 31, 2016 82,000 $ 2.74 2.69

Fair Value of Financial Instr16

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The estimated fair value of the Company’s assets and liabilities as of March 31, 2016 and December 31, 2015 were as follows (in thousands): Level 1 Level 2 Level 3 Total Carrying March 31, 2016 Assets: Cash, cash equivalents, restricted cash $ 2,190 $ - $ - $ 2,190 $ 2,190 Investment in equity securities - - 579 579 579 Total $ 2,190 $ - $ 579 $ 2,769 $ 2,769 Liabilities Debt obligations $ - $ - $ 8,321 $ 8,321 $ 8,204 Total $ - $ - $ 8,321 $ 8,321 $ 8,204 December 31, 2015 Assets: Cash, cash equivalents, restricted cash $ 2,259 $ - $ - $ 2,259 $ 2,259 Investment in equity securities - - 579 579 579 Total $ 2,259 $ - $ 579 $ 2,838 $ 2,838 Liabilities Debt obligations $ - $ - $ 9,744 $ 9,744 $ 9,525 Total $ - $ - $ 9,744 $ 9,744 $ 9,525

Basis of Presentation (Details

Basis of Presentation (Details Textual) - USD ($)	Jan. 14, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Debt obligations, Carrying Value		$ 8,204,000		$ 9,525,000
Payments to Acquire Property, Plant, and Equipment, Total		333,000	$ 188,000
Loss on early extinguishment of debt		(108,000)	$ 0
Accounting Standards Update 2015-03 [Member]
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets		67,000		$ 72,000
Notes Payable [Member]
Debt Instrument, Face Amount		145,000
Unamortized discount on Notes		80,000
Deferred fees from issuance of Note		$ 28,000
Mevion Medical Systems Inc [Member]
Proceeds from Long-term Capital Lease Obligations	$ 7,900,000
Debt obligations, Carrying Value	8,400,000
Repayments of Notes Payable	1,000,000
Purchase Commitment, Remaining Minimum Amount Committed	6,700,000
Payments to Acquire Property, Plant, and Equipment, Total	$ 1,137,000
OR21 LLC [Member]
Equity Method Investment, Ownership Percentage		50.00%
Architectural Design Company [Member]
Equity Method Investment, Ownership Percentage		50.00%

Per Share Amounts (Details)

Per Share Amounts (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Net income attributable to American Shared Hospital Services	$ 51,000	$ 128,000
Weighted average common shares for basic earnings per share	5,541,000	5,477,000
Diluted effect of stock options and restricted stock	0	49,000
Weighted average common shares for diluted earnings per share	5,541,000	5,526,000
Basic earnings per share	$ 0.01	$ 0.02
Diluted earnings per share	$ 0.01	$ 0.02

Per Share Amounts (Details Text

Per Share Amounts (Details Textual) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	617,000	617,000

Stock-based Compensation (Detai

Stock-based Compensation (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Shareholders Equity [Line Items]
Nonvested, Number of Options, Outstanding | shares	3,000
Nonvested, Number of Options, Granted | shares	32,000
Nonvested, Number of Options, Vested | shares	(8,000)
Nonvested, Number of Options, Forfeited | shares	0
Nonvested, Number of Options, Outstanding | shares	27,000
Weighted Average Grant-Date Fair Value, Nonvested, Outstanding	$ 2.58
Weighted Average Grant-Date Fair Value, Nonvested, Granted	1.89
Weighted Average Grant-Date Fair Value, Nonvested, Vested	1.89
Weighted Average Grant-Date Fair Value, Nonvested, Forfeited	0
Weighted Average Grant-Date Fair Value, Nonvested, Outstanding	1.97
Intrinsic Value, Outstanding	0
Intrinsic Value, Granted	0
Intrinsic Value, Vested	0
Intrinsic Value, Forfeited	0
Intrinsic Value, Outstanding	$ 7,000

Stock-based Compensation (Det21

Stock-based Compensation (Details 1) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Schedule Of Share Based Compensation Stock Options Activity [Line Items]
Number of Options, Beginning balance	614,000
Number of Options, Granted	3,000
Number of Options, Exercised	0
Number of Options, Forfeited	0
Number of Options, Ending balance	617,000	614,000
Number of Options, Exercisable	82,000
Weighted Average Exercise Price, Beginning balance	$ 2.86
Weighted Average Exercise Price, Granted	1.90
Weighted Average Exercise Price - Exercised	0
Weighted Average Exercise Price, Forfeited	0
Weighted Average Exercise Price, Ending balance	2.85	$ 2.86
Grant Date Weighted Average Exercise Price, Exercisable	$ 2.74
Weighted Average Remaining Contractual Life (Years), Balance	4 years 10 months 10 days	5 years 1 month 6 days
Weighted Average Remaining Contractual Life (Years), Granted	6 years 11 months 8 days
Weighted Average Remaining Contractual Life (Years), Exercisable	2 years 8 months 8 days

Stock-based Compensation (Det22

Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Jun. 02, 2010
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share Based Compensation Expense	$ 59,000	$ 36,000
Incentive Compensation Plan [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance			880,000
Share-based Compensation, Compensation Cost Not yet Recognized	$ 440,000
Incentive Compensation Plan [Member] | Maximum [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance			1,630,000
Incentive Compensation Plan [Member] | Minimum [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance			750,000

Investment in Equity Securiti23

Investment in Equity Securities (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 31, 2016
Schedule of Cost-method Investments [Line Items]
Equity Method Investments	$ 579,000	$ 579,000
Mevion Medical Systems Inc [Member]
Schedule of Cost-method Investments [Line Items]
Equity Method Investments	579,000	$ 579,000
Equity Method Investment, Ownership Percentage		0.46%
Investments, Fair Value Disclosure	579,000
Other than Temporary Impairment Losses, Investments	$ 2,140,000

Fair Value of Financial Instr24

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Assets, Carrying Value:
Cash, cash equivalents, restricted cash, Carrying Value	$ 2,190	$ 2,259
Investment in equity securities, Carrying Value	579	579
Total, Carrying Value	2,769	2,838
Liabilities, Carrying Value
Debt obligations, Carrying Value	8,204	9,525
Total, Carrying Value	8,204	9,525
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	2,190	2,259
Investment in equity securities, Fair Value	579	579
Total, Fair Value	2,769	2,838
Liabilities, Fair Value
Debt obligations, Fair Value	8,321	9,744
Total, Fair Value	8,321	9,744
Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	2,190	2,259
Investment in equity securities, Fair Value	0	0
Total, Fair Value	2,190	2,259
Liabilities, Fair Value
Debt obligations, Fair Value	0	0
Total, Fair Value	0	0
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	0	0
Investment in equity securities, Fair Value	0	0
Total, Fair Value	0	0
Liabilities, Fair Value
Debt obligations, Fair Value	0	0
Total, Fair Value	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	0	0
Investment in equity securities, Fair Value	579	579
Total, Fair Value	579	579
Liabilities, Fair Value
Debt obligations, Fair Value	8,321	9,744
Total, Fair Value	$ 8,321	$ 9,744

Repurchase of Common Stock (Det

Repurchase of Common Stock (Details Textual) - shares	Mar. 31, 2016	Dec. 31, 2008
Equity, Class of Treasury Stock [Line Items]
Stock Repurchase Program, Number of Shares Authorized to be Repurchased		1,000,000
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased	72,000